• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:刘晓华,姚景春,高睿智,崔翰文,范建伟,杨梅,魏永佳.连翘苷元纳米晶制剂在大鼠体内的药代动力学及生物利用度[J].药学研究,2026,45(6):651-655[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 1184次   下载 657次 本文二维码信息
码上扫一扫!
连翘苷元纳米晶制剂在大鼠体内的药代动力学及生物利用度
刘晓华1,姚景春2,高睿智1,崔翰文1,范建伟3,杨梅3,4,魏永佳1
字体:加大+|默认|缩小-
(1.黑龙江省医院,黑龙江 哈尔滨 150036;2.鲁南制药集团新药药理中心,山东 临沂 273499;3.鲁南制药集团经方与现代中药融合创新全国重点实验室,山东 临沂 276005;4.鲁南厚普制药有限公司,山东 临沂 276005)
摘要:
目的 评价连翘苷元(PHI)不同制剂在大鼠体内的药代动力学行为,探讨纳米晶制剂对口服生物利用度的改善作用。方法 将15只SD大鼠分为3组,分别静脉注射PHI注射液(5 mg·kg-1)或灌胃PHI粗混悬液、PHI纳米晶(100 mg·kg-1)。于给药后多个时间点采血,采用超高效液相色谱串联质谱(UPLC-MS/MS)法测定血药浓度,利用DAS 2.0计算药动学参数及绝对生物利用度,并进行组间比较。结果 静脉注射PHI后血药浓度迅速达峰并快速下降;与粗混悬液组相比,PHI纳米晶组的AUC0-∞、Cmax均升高(P<0.05),Tmax提前,表观清除率CLz/F降低(P<0.05),t1/2z差异无统计学意义。绝对生物利用度由粗混悬液的1.20%提升至13.06%(P<0.01)。结论 PHI纳米晶制剂能提高口服吸收速率与生物利用度,改善药动学特性,为其作为抗纤维化口服制剂的开发提供实验依据。
关键词:  连翘苷元  纳米晶  药代动力学  超高效液相色谱串联质谱  生物利用度  大鼠
DOI:10.13506/j.cnki.jpr.2026.06.007
基金项目:
收稿日期:2026-01-30   修回日期:2026-04-07  
Pharmacokinetics and bioavailability of phillygenin nanocrystalline formulation in rats
LIU Xiaohua1,YAO Jingchun2,GAO Ruizhi1,CUI Hanwen1,FAN Jianwei3,YANG Mei3,4,WEI Yongjia1
(1. Heilongjiang Provincial Hospital, Harbin 150036, China;2. Lunan Pharmaceutical Group New Drug Pharmacology Center, Linyi 273499,China;3. State Key Laboratory of Integration and Innovation of Classic Formula and Modern Chinese Medicine, Lunan Pharmaceutical Group Co., Ltd., Linyi 276006, China;4.Lunan Houpu Pharmaceutical Co., Ltd., Linyi 276005,China)
Abstract:
Objective To evaluate the pharmacokinetic behavior of different Phillygenin (PHI) formulations in rats and investigate the improvement in oral bioavailability by its nanocrystalline formulation. Methods Fifteen Sprague-Dawley rats were divided into three groups, receiving either an intravenous injection of PHI solution (5 mg·kg-1) or oral administration of a coarse PHI suspension or PHI nanocrystals (both at 100 mg·kg-1). Blood samples were collected at multiple time points post-dose. Plasma PHI concentrations were determined by UPLC-MS/MS, and pharmacokinetic parameters along with absolute bioavailability were calculated using DAS 2.0 software. And group comparisons were performed. Results Following intravenous administration, plasma PHI concentration peaked rapidly and declined quickly. Compared with the coarse suspension group, the PHI nanocrystal group showed significantly increased AUC0-∞ and Cmax(P<0.05), significantly shortened Tmax, and significantly decreased apparent clearance CLz/F (P<0.05), while no significant difference was observed in t1/2z. The absolute bioavailability was significantly increased from 1.20% for the coarse suspension to 13.06% for the nanocrystals (P<0.01). Conclusion The PHI nanocrystalline formulation significantly improves the oral absorption rate, bioavailability, and pharmacokinetic profile. These findings provide an experimental basis for its development as an oral anti-fibrotic agent.
Key words:  Forsythia glycosides  Nanocrystals  pharmacokinetics  UPLC-MS/MS  Bioavailability  Rats
今日访问量:2433    总访问量:55338849
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司